Exelixis
EXEL
#1343
Rank
S$20.74 B
Marketcap
S$85.00
Share price
-3.60%
Change (1 day)
54.45%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

P/S ratio for Exelixis (EXEL)

P/S ratio as of November 2026 (TTM): 6.43

According to Exelixis's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 8.76. At the end of 2026 the company had a P/S ratio of 5.79.

P/S ratio history for Exelixis from 2001 to 2026

PS ratio at the end of each year

Year P/S ratio Change
20265.7914.59%
20255.0613.58%
20244.459.22%
20234.0826.93%
20223.21-20.32%
20214.03-36.08%
20206.3113.98%
20195.53-19.92%
20186.91-65.24%
201719.9-11.96%
201622.6-34.72%
201534.6207.89%
201411.2-68.88%
201336.1104.02%
201217.7698.31%
20112.22-54.29%
20104.85-7.48%
20095.2416.52%
20084.50-43.54%
20077.97-9.01%
20068.76-15.35%
200510.3-23.26%
200413.538.21%
20039.75-9.02%
200210.7-52.9%
200122.8

P/S ratio for similar companies or competitors

Company P/S ratio P/S ratio differencediff. Country
Johnson & Johnson
JNJ
6.47 0.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
2.47-61.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
6.10-5.16%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
1.89-70.69%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
4.86-24.47%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
2.38-62.95%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
2.15-66.62%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
1.04-83.91%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
5.53-14.06%๐Ÿ‡บ๐Ÿ‡ธ USA